Malta - English - Medicines Authority

alta care laboratoires piazza di spagna 6, 00187 roma, italy - cetirizine hydrochloride - film-coated tablet - cetirizine hydrochloride 10 mg - antihistamines for systemic use

Malta - English - Medicines Authority

alta care laboratoires piazza di spagna 6, 00187 roma, italy - ferrous gluconate - effervescent tablet - ferrous gluconate 695 mg - antianemic preparations

Malta - English - Medicines Authority

alta care laboratoires piazza di spagna 6, 00187 roma, italy - cefaclor - granules for oral suspension - cefaclor 250 mg/5ml - antibacterials for systemic use

Malta - English - Medicines Authority

alta care laboratoires piazza di spagna 6, 00187 roma, italy - cefaclor - hard capsule - cefaclor 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

alta care laboratoires piazza di spagna 6, 00187 roma, italy - piroxicam - gel - piroxicam 1 % (w/w) - topical products for joint and muscular pain

Malta - English - Medicines Authority

alta care laboratoires piazza di spagna 6, 00187 roma, italy - aciclovir - cream - aciclovir 5 % (w/w) - antibiotics and chemotherapeutics for dermatological use

Malta - English - Medicines Authority

alta care laboratoires piazza di spagna 6, 00187 roma, italy - amoxicillin - tablet - amoxicillin 1000 mg - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

lake erie medical surgical & supply dba quality care products llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short-term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - cymbalta is indicated for the treatment of major depressive disorder (mdd). the efficacy of cymbalta was established in four short term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. cymbalta is indicated for the treatment of generalized anxiety disorder (gad). the efficacy of cymbalta was established in three short-term trials and one maintenance trial in adults [see clinical studies (14.2)] . generalized anxiety disorder is defined by the dsm

United States - English - NLM (National Library of Medicine)

eli lilly and company - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - cymbalta® is indicated for the treatment of: - major depressive disorder in adults - generalized anxiety disorder in adults and pediatric patients 7 years of age and older - diabetic peripheral neuropathic pain in adults - fibromyalgia in adults and pediatric patients 13 years of age and older - chronic musculoskeletal pain in adults the use of maois intended to treat psychiatric disorders with cymbalta or within 5 days of stopping treatment with cymbalta is contraindicated because of an increased risk of serotonin syndrome. the use of cymbalta within 14 days of stopping an maoi intended to treat psychiatric disorders is contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)] . starting cymbalta in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions (5.4)] . pregnancy exposure registry there